Omada Health hit a key profitability milestone at the end of 2025 as it brought in net income of $5 million in the fourth quarter, its first profitable quarter.
The virtual chronic care provider also reported strong revenue growth for 2025 and the fourth quarter, buoyed by steady growth in adoption of its hypertension and diabetes support and GLP-1 program.
Omada Health's membership grew 55% year over year to 886,000. Fourth-quarter revenue was up 58% to reach $76 million, and full-year revenue came to $260 million, up 53% compared to 2024. The company's net profit in the fourth quarter compares with a net loss of $8 million in the same quarter a year ago. For the full year, Omada narrowed its losses, reporting a net loss of $13 million for the year compared with a net loss of $47 million in 2024.
Omada also reported adjusted EBITDA of $8 million in the fourth quarter, compared with an adjusted EBITDA loss of $4 million in the fourth quarter of 2024. For the full year, the company reported adjusted EBITDA of $6 million compared with an adjusted EBITDA loss of $29 million in 2024.
Gross margins expanded to 71% in the fourth quarter, up from 67% in the fourth quarter of 2024, and gross margin of 66% for the year compared with 61% a year ago.
"The primary factors driving growth include a broad industry focus on cardiometabolic conditions, deeper penetration of multi-condition customers, strong adoption of our GLP-1 programs and more effective enrollment campaigns," said Steven Cook, Omada's chief financial officer, during the company's full-year and fourth-quarter earnings call.
Revenue from Omada's weight loss program grew more than 50% in 2025, and revenue from the hypertension and diabetes programs grew at rates of 45% or more, executives noted, as employers lean into Omada Health as an integrated cardiometabolic solutions provider.
The company ended 2025 with $222 million of cash and cash equivalents, up from $199 million at the end of the third quarter. And it generated positive operating cash flow for the full year, marking a significant milestone, Cook told investors.
Omada Health, which went public in June, ties remote monitoring devices with coaching and artificial intelligence to help consumers control their chronic diseases. The company supports diabetes, hypertension, obesity and musculoskeletal conditions and leans on its multi-condition approach to differentiate itself from competitors. The company works with 2,000 employers and health plans today.
In 2023, it launched its GLP-1 Care Track, which provides support and wraparound services to health plan members and employees who are taking GLP-1 medications. The company didn't initially offer access to GLP-1 medication prescriptions but instead focused on building out its weight management program. It decided to jump into the GLP-1 market last year, announcing a GLP-1 care companion solution that can include nutrition guidance, education and a care team of health coaches, cardiometabolic specialists or exercise specialists, as well as prescribing and medication management.
To make further inroads into the obesity market, the company last week unveiled GLP-1 Flex Care, a new offering that supports employers looking to increase access to GLP-1 medications for obesity. Members purchase their medications independently through cash-pay channels, helping employers limit their direct exposure to medication costs, according to the company.
"The need for alternative GLP-1 benefit in design solutions is underappreciated and we believe this could represent a significant opportunity. The GLP-1 market for large commercially insured employers is currently split, roughly 45% covering GLP-1s for obesity and roughly 55% that don't," Wei-Li Shao, Omada Health's president, said during the earnings call.
"That 55% that aren't covering GLP-1s need something different before moving from waiting and watching to confidently covering," he noted. "That's where GLP-1 Flex Care comes in. It gives employers a structured way to connect eligible employees with clinical evaluation, prescribing and ongoing medical oversight for GLP-1 alongside Omada's lifestyle and behavioral support."
With this program, employers pay for the doctors' visits, labs and behavioral support while employees purchase branded GLP-1s out-of-pocket through credible cash pay channels.
"We believe the future for GLP-1 coverage will include multiple benefit design solutions addressing diverse employer needs, including robust clinical services, broad GLP-1 access, lifestyle support and financial reassurance," Shao said.
The new program enables employers that do not cover anti-obesity medications to still offer their employees a chance for high-quality GLP-1 care "with strong oversight without immediately taking on that full drug spend risk," Sean Duffy, Omada Health CEO and co-founder, told investors on the earnings call.
Omada has now supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024.
"Omada's technology and operational platform, our clinical programs, our peer-reviewed research, productive distribution channels and more than a decade of rich and unique data are strongly suited for this exact moment, for when customer demand for chronic care solutions, a rapidly evolving GLP-1 marketplace and AI-driven innovation converge," Duffy said.
Omada is on a mission to bend the curve of obesity-related disease, Duffy said, as 40% of adults have obesity and nearly two-thirds have at least one cardiometabolic risk factor such as obesity, diabetes, hypertension or cardiovascular disease. “We believe the health care system is structurally unable to address this at scale without a fundamentally different care model," he noted.
A person's disease trajectory is determined largely outside the doctor's office, Duffy added.
“Omada puts the space between those visits at the center of care through an integrated multi-condition care model refined over more than a decade. We've built a member experience that brings together care teams, AI, connected devices and a custom care platform designed for quality at scale,” Duffy said.
Omada’s results have shown that GLP-1 Care Track members on average achieved greater weight loss, compared with published real-world evidence and critically largely maintained their weight on average, one year after discontinuing GLP-1 therapy. “These outcomes challenge the narrative of inevitable weight rebound and underscore the power of behavior change layered on top of medication,” Duffy said.
Omada is bullish on policy tailwinds to drive tech-enabled chronic condition management such as the Prevent Diabetes Act, which cemented Medicare coverage for virtual diabetes prevention programs, and the CMS ACCESS model. "This government activity reinforces that virtual first prevention is increasingly recognized as essential to expanding access to quality care," Shao told investors.
The digital health company has also made significant investments in AI, embedding the technology throughout its platform. OmadaSpark is an AI-powered assistant that works alongside human coaches for real-time nutritional support, motivational challenges and habit building, while Meal Map is an AI-driven experience focused on food quality.
Care teams have access to AI-enabled tools like summarization to spend less time on paperwork. Omada engineers are also equipped with AI-assisted coding tools to improve development speed and output.
In response to an investor's questions about the potential risks of AI disruption to Omada's business, Duffy said the company has unique data sets, "tens of millions of care team conversations, hundreds of millions of biometric data points and billions of real-world data points, that enables it to customize and personalize care." This data foundation gives the company a unique advantage, he noted.
"I don't tend to view it as if AI will disrupt healthcare or disrupt Omada, rather, I view it as a question of who is going to build it in the right way in healthcare. And I believe we have the unique foundations to do just that here at Omada," he said on the call.
The company is guiding toward 2026 revenue in the range of $312 million to $322 million, with the midpoint reflecting 22% growth over 2025. Omada also expects 2026 adjusted EBITDA in the range of $7 million to $15 million, with the midpoint reflecting a $5 million increase compared to last year.